News
Allogeneic CAR-T cells get edited and show safety - Highlights from AACR
The use of CAR-T cells from healthy donors, or allo CAR-T, has long struggled with intrinsic challenges — notably the host’s immune system rejecting the donated CAR-T cells or vice versa, the CAR-T cells attacking the patient’s healthy cells in graft versus host disease. At the AACR annual meeting this year, two abstracts showed new data outlining progress in allo CAR-T products edited for better safety, stronger resistance, and increased potency.
Source: STAT News